Scotland, Graham; Waugh, Norman; Royle, Pamela; … - In: PharmacoEconomics 29 (2011) 11, pp. 951-961
The National Institute for Health and Clinical Excellence (NICE) invited the manufacturer of denosumab (Amgen Inc., UK) to submit evidence for the clinical and cost effectiveness of denosumab for the prevention of fragility fractures in post-menopausal women, as part of the Institute's single...